Full Title
Phase II Study to Examine Precision Radiation in Patients with Pathogenic Mutations in ATMPurpose
Radiation delivered to metastatic tumors is known to cause damage to the DNA (genetic information) in the cancer cells, which causes them to die. An ATM mutation reduces cancer cells’ ability to fix damage to their DNA, making it more likely that the radiation will kill ATM-mutated cancer cells. Lower doses of radiation therapy may cause fewer side effects than standard doses. In this study, researchers will observe the side effects of reduced-dose radiation therapy in patients with metastatic tumors that contain an ATM mutation and the rate at which tumors grow back (recur) after this treatment. It is hoped that lowering the radiation dose will be effective while reducing the side effects of treatment.
Protocol
21-310
Phase
Phase II (phase 2)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05010031
ClinicalTrials.gov